HIGH POINT, N.C.--(BUSINESS WIRE)--Banner Pharmacaps Inc., a leader in the pharmaceutical industry for the development of soft gelatin dosage form technology, today announced that the US Food & Drug Administration has granted approval for the Company’s Abbreviated New Drug Application (ANDA) for Nimodipine 30 mg soft gelatin capsules.
